Dahlene N Fusco
Overview
Explore the profile of Dahlene N Fusco including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
665
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang B, Fong Y, Dang L, Fintzi J, Chen S, Wang J, et al.
Nat Commun
. 2025 Jan;
16(1):759.
PMID: 39824819
Neutralizing antibody titer has been a surrogate endpoint for guiding COVID-19 vaccine approval and use, although the pandemic's evolution and the introduction of variant-adapted vaccine boosters raise questions as to...
2.
Fong Y, Dang L, Zhang B, Fintzi J, Chen S, Wang J, et al.
Clin Infect Dis
. 2024 Sep;
80(1):223-227.
PMID: 39325506
For COVAIL recipients of a coronavirus disease 2019 (COVID-19) Sanofi booster vaccine, neutralizing antibody titers were assessed as a correlate of risk (CoR) of COVID-19. Peak and exposure-proximal titers were...
3.
Sise M, Santos J, Goldman J, Tuttle K, Teixeira J, Seibert A, et al.
Clin Infect Dis
. 2024 Jun;
79(5):1172-1181.
PMID: 38913574
Background: Few antiviral therapies have been studied in patients with coronavirus disease 2019 (COVID-19) and kidney impairment. Herein, the efficacy, safety, and pharmacokinetics of remdesivir, its metabolites, and sulfobutylether-β-cyclodextrin excipient...
4.
Salvadori N, Fridman M, Chiang M, Chen L, Wang C, Lee E, et al.
Front Med (Lausanne)
. 2024 May;
11:1390164.
PMID: 38818394
Background: The direct acting antiviral remdesivir (RDV) has shown promising results in randomized clinical trials. This study is a unique report of real clinical practice RDV administration for COVID-19 from...
5.
Branche A, Rouphael N, Diemert D, Falsey A, Losada C, Baden L, et al.
Nat Med
. 2023 Aug;
29(9):2334-2346.
PMID: 37640860
Vaccine protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection wanes over time, requiring updated boosters. In a phase 2, open-label, randomized clinical trial with sequentially enrolled stages at...
6.
Rouphael N, Branche A, Diemert D, Falsey A, Losada C, Baden L, et al.
J Infect Dis
. 2023 Aug;
228(12):1662-1666.
PMID: 37561027
We compared the serologic responses of 1 dose versus 2 doses of a variant vaccine (Moderna mRNA-1273 Beta/Omicron BA.1 bivalent vaccine) in adults. A 2-dose boosting regimen with a variant...
7.
Rouphael N, Branche A, Diemert D, Falsey A, Losada C, Baden L, et al.
medRxiv
. 2023 Jun;
PMID: 37333252
In this brief report, we compare the magnitude and durability of the serologic response of one versus two doses (separated by 56 days) of a variant vaccine (Moderna mRNA-1273 Beta/Omicron...
8.
Branche A, Rouphael N, Losada C, Baden L, Anderson E, Luetkemeyer A, et al.
Clin Infect Dis
. 2023 Apr;
77(4):560-564.
PMID: 37036397
In a randomized clinical trial, we compare early neutralizing antibody responses after boosting with bivalent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA (mRNA) vaccines based on either BA.1...
9.
Branche A, Rouphael N, Losada C, Baden L, Anderson E, Luetkemeyer A, et al.
medRxiv
. 2023 Apr;
PMID: 37034641
In a randomized clinical trial, we compare early neutralizing antibody responses after boosting with bivalent SARS-CoV-2 mRNA vaccines based on either BA.1 or BA.4/BA.5 Omicron spike protein combined with wildtype...
10.
Branche A, Rouphael N, Diemert D, Falsey A, Losada C, Baden L, et al.
medRxiv
. 2022 Jul;
PMID: 35898343
Background: Protection from SARS-CoV-2 vaccines wanes over time and is compounded by emerging variants including Omicron subvariants. This study evaluated safety and immunogenicity of SARS-CoV-2 variant vaccines. Methods: This phase...